AVTX insider transaction filings
Avalo Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-18. Screen AVTX transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 14 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 12 legs across 10 filings by 3 insiders — 107,421 shares, $2,070,666 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 28.
- Largest priced transaction: sale of 37,945 shares @ $19.85 ($753,333) by Sullivan Christopher Ryan, filed 2026-08-19.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Sullivan Christopher Ryan — Chief Financial Officer | 3 | — | 5 legs · 95,304 sh · $1,832,313 | 10 |
| Doyle Mittie — Chief Medical Officer | 6 | — | 6 legs · 9,462 sh · $186,340 | 14 |
| Riley Jennifer — Chief Strategy Officer | 1 | — | 1 leg · 2,655 sh · $52,012 | — |
| Philip Ron M — Director | 2 | — | — | 2 |
| Jain Rita — Director | 1 | — | — | 1 |
| Lind Kevin Robert — Director | 1 | — | — | 1 |
Recent Form 4 filings — Avalo Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-18 | 4 | Sullivan Christopher Ryan — Chief Financial Officer | Option exercise (M): 12,394 @ $9.88 · Sale (S): 12,394 @ $16.33 · Option exercise (M): 12,394 (derivative) @ $0 | EDGAR |
| 2026-09-11 | 4 | Sullivan Christopher Ryan — Chief Financial Officer | Option exercise (M): 10,185 @ $8.04 · Sale (S): 10,185 @ $17.62 · Option exercise (M): 10,185 (derivative) @ $0 | EDGAR |
| 2026-09-01 | 4 | Doyle Mittie — Chief Medical Officer | Option exercise (M): 679 @ $8.04 · Sale (S): 679 @ $20 · Option exercise (M): 679 (derivative) @ $0 | EDGAR |
| 2026-08-19 | 4 | Doyle Mittie — Chief Medical Officer | Option exercise (M): 1,000 @ $12.65 · Sale (S): 1,000 @ $20 · Option exercise (M): 1,000 (derivative) @ $0 | EDGAR |
| 2026-08-19 | 4 | Sullivan Christopher Ryan — Chief Financial Officer | Option exercise (M): 37,945 @ $9.88 · Option exercise (M): 2,876 @ $9.88 · Sale (S): 37,945 @ $19.85 · Sale (S): 3,749 @ $19.94 · Option exercise (M): 31,031 @ $9.88 · Sale (S): 31,031 @ $20.05 · +3 more | EDGAR |
| 2026-08-12 | 4 | Doyle Mittie — Chief Medical Officer | Option exercise (M): 679 @ $8.04 · Sale (S): 679 @ $20 · Option exercise (M): 679 (derivative) @ $0 | EDGAR |
| 2026-08-12 | 4 | Riley Jennifer — Chief Strategy Officer | Sale (S): 2,655 @ $19.59 | EDGAR |
| 2026-07-29 | 4 | Doyle Mittie — Chief Medical Officer | Option exercise (M): 1,000 @ $12.65 · Sale (S): 1,000 @ $20 · Option exercise (M): 1,000 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Philip Ron M — Director | Grant/award (A): 69 (derivative) @ $15.04 | EDGAR |
| 2026-07-02 | 4 | Doyle Mittie — Chief Medical Officer | Option exercise (M): 2,875 @ $12.65 · Option exercise (M): 1,779 @ $8.04 · Sale (S): 4,654 @ $20 · Option exercise (M): 2,875 (derivative) @ $0 · Option exercise (M): 1,779 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Jain Rita — Director | Grant/award (A): 1,080 (derivative) @ $15.04 | EDGAR |
| 2026-07-02 | 4 | Lind Kevin Robert — Director | Grant/award (A): 1,105 (derivative) @ $15.04 | EDGAR |
| 2026-06-25 | 4 | Philip Ron M — Director | Grant/award (A): 40,200 (derivative) @ $0 | EDGAR |
| 2026-06-25 | 4 | Doyle Mittie — Chief Medical Officer | Option exercise (M): 1,450 @ $8.04 · Sale (S): 1,450 @ $18 · Option exercise (M): 1,450 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Riley Jennifer — Chief Strategy Officer | Tax withholding (F): 588 @ $13.10 | EDGAR |
| 2026-06-12 | 4 | Doyle Mittie — Chief Medical Officer | Tax withholding (F): 1,084 @ $13.10 | EDGAR |
| 2026-06-12 | 4 | Sullivan Christopher Ryan — Chief Financial Officer | Tax withholding (F): 138 @ $13.10 | EDGAR |
| 2026-06-12 | 4 | VARKI PAUL — Chief Legal Officer | Tax withholding (F): 1,081 @ $13.10 | EDGAR |
| 2026-06-04 | 4 | Truex Samantha — Director | Grant/award (A): 20,100 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | KANTOFF AARON — Director | Grant/award (A): 20,100 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Jain Rita — Director | Grant/award (A): 20,100 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Lind Kevin Robert — Director | Grant/award (A): 20,100 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Heffernan Michael Thomas — Director | Grant/award (A): 29,500 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | KAPLAN GILLA — Director | Grant/award (A): 20,100 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Doyle Mittie — Chief Medical Officer | Option exercise (M): 679 @ $8.04 · Sale (S): 679 @ $16 · Option exercise (M): 679 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | Riley Jennifer — Chief Strategy Officer | Grant/award (A): 34,200 @ $0 | EDGAR |
| 2026-05-26 | 4 | Doyle Mittie — Chief Medical Officer | Grant/award (A): 43,500 @ $0 | EDGAR |
| 2026-05-26 | 4 | Sullivan Christopher Ryan — Chief Financial Officer | Grant/award (A): 39,900 @ $0 | EDGAR |
| 2026-05-26 | 4 | VARKI PAUL — Chief Legal Officer | Grant/award (A): 24,300 @ $0 | EDGAR |
| 2026-05-26 | 4 | NEIL GARRY ARTHUR — Chief Executive Officer, Director | Grant/award (A): 100,200 @ $0 | EDGAR |
| 2026-05-19 | 4 | Doyle Mittie — Chief Medical Officer | Option exercise (M): 3,000 @ $12.65 · Sale (S): 3,000 @ $18.76 · Option exercise (M): 3,000 (derivative) @ $0 | EDGAR |
| 2026-05-11 | 4 | Sullivan Christopher Ryan — Chief Financial Officer | Option exercise (M): 18,606 @ $9.88 · Sale (S): 18,606 @ $24.12 · Option exercise (M): 18,606 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | Doyle Mittie — Chief Medical Officer | Option exercise (M): 1,000 @ $12.65 · Option exercise (M): 679 @ $8.04 · Sale (S): 1,679 @ $16 · Option exercise (M): 77,905 @ $12.65 · Option exercise (M): 28,650 @ $8.04 · Sale (S): 27,538 @ $18.03 · +8 more | EDGAR |
| 2026-05-07 | 4 | Sullivan Christopher Ryan — Chief Financial Officer | Option exercise (M): 47,000 @ $8.04 · Sale (S): 13,834 @ $18.55 · Sale (S): 12,347 @ $19.28 · Sale (S): 2,700 @ $20.76 · Sale (S): 9,219 @ $21.37 · Sale (S): 8,900 @ $22.57 · +1 more | EDGAR |
| 2026-05-07 | 4 | Chan Mitchell — Director | Sale (S): 3,167 @ $22.88 | EDGAR |
| 2026-05-07 | 4 | VARKI PAUL — Chief Legal Officer | Option exercise (M): 62,500 @ $13.43 · Option exercise (M): 12,563 @ $8.04 · Sale (S): 37,375 @ $18.91 · Sale (S): 5,196 @ $19.78 · Sale (S): 22,839 @ $21.22 · Sale (S): 9,253 @ $22.70 · +3 more | EDGAR |
| 2026-05-01 | 4 | Sullivan Christopher Ryan — Chief Financial Officer | Sale (S): 8,458 @ $13.09 · Sale (S): 8,457 @ $13.23 | EDGAR |
| 2026-04-08 | 4 | Doyle Mittie — Chief Medical Officer | Option exercise (M): 3,970 @ $12.65 · Sale (S): 3,970 @ $18.01 · Option exercise (M): 3,970 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Doyle Mittie — Chief Medical Officer | Option exercise (M): 679 @ $8.04 · Sale (S): 679 @ $16 · Option exercise (M): 679 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Sullivan Christopher Ryan — Chief Financial Officer | Sale (S): 500 @ $15.86 · Sale (S): 7,479 @ $16.83 · Sale (S): 6,200 @ $17.02 · Sale (S): 1,780 @ $17.57 | EDGAR |
| 2026-04-01 | 4 | Jain Rita — Director | Grant/award (A): 1,339 (derivative) @ $12.13 | EDGAR |
| 2026-04-01 | 4 | Lind Kevin Robert — Director | Grant/award (A): 1,370 (derivative) @ $12.13 | EDGAR |
| 2026-03-31 | 4 | Truex Samantha — Director | Option exercise (M): 3,166 · Option exercise (M): 3,166 (derivative) @ $0 | EDGAR |
| 2026-03-31 | 4 | Goldman Jonathan — Director | Option exercise (M): 3,166 · Option exercise (M): 3,166 (derivative) @ $0 | EDGAR |
| 2026-03-31 | 4 | KANTOFF AARON — Director | Option exercise (M): 3,166 · Option exercise (M): 3,166 (derivative) @ $0 | EDGAR |
| 2026-03-31 | 4 | Sullivan Christopher Ryan — Chief Financial Officer | Option exercise (M): 24,200 · Tax withholding (F): 8,241 @ $13.89 · Option exercise (M): 24,200 (derivative) @ $0 | EDGAR |
| 2026-03-31 | 4 | Chan Mitchell — Director | Option exercise (M): 3,166 · Option exercise (M): 3,166 (derivative) @ $0 | EDGAR |
| 2026-03-31 | 4 | NEIL GARRY ARTHUR — Chief Executive Officer, Director | Option exercise (M): 64,866 · Tax withholding (F): 21,892 @ $13.89 · Option exercise (M): 64,866 (derivative) @ $0 | EDGAR |
| 2026-03-31 | 4 | KAPLAN GILLA — Director | Option exercise (M): 3,166 · Option exercise (M): 3,166 (derivative) @ $0 | EDGAR |
| 2026-03-18 | 4 | Doyle Mittie — Chief Medical Officer | Option exercise (M): 19,500 @ $12.65 · Option exercise (M): 5,992 @ $8.04 · Sale (S): 25,492 @ $16.15 · Option exercise (M): 19,500 (derivative) @ $0 · Option exercise (M): 5,992 (derivative) @ $0 | EDGAR |
Recent 8-K events — Avalo Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-23 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-16 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-12 | 8-K | 3.02 — Unregistered Sales of Equity Securities 3.03 — Material Modification to Rights of Security Holders 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-08 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-05 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-28 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-27 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=AVTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →